Get the Stockscreener App
17.44
3.01%
0.51
Acadia Pharmaceuticals Inc stock is traded at $17.44, with a volume of 2.85M.
It is up +3.01% in the last 24 hours and up +16.58% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$16.93
Open:
$16.84
24h Volume:
2.85M
Relative Volume:
1.67
Market Cap:
$2.49B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
96.89
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
+16.97%
1M Performance:
+16.58%
6M Performance:
-1.25%
1Y Performance:
+14.66%
1-Day Range:
$16.76
$17.62
1-Week Range:
$14.45
$17.62
52-Week Range:
$13.40
$20.68
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
17.44 | 2.49B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Acadia Pharmaceuticals (ACAD) Prepares for Stock Sale by Shareho - GuruFocus
Acadia Pharmaceuticals Inc Files For Offering Of Up To 43.6 Million Shares Of Common Stock By The Selling StockholdersSEC Filing - marketscreener.com
Acadia Pharmaceuticals (ACAD) Prepares for Stock Sale by Shareholders - GuruFocus
Acadia Pharma (ACAD) Files for 43.58M Share Offering by Selling Stockholders - StreetInsider
New Parkinson's Disease Therapies Market Outlook & Research - openPR.com
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data - MSN
ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth - TipRanks
Schizophrenia Market Growth Projections 2024-2034: - openPR.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Call Transcript - Insider Monkey
Acadia: Q1 Earnings Snapshot - Norwalk Hour
Cautious Hold Rating on ACADIA Pharmaceuticals Amid Mixed Performance and Future Prospects - TipRanks
Acadia Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview - BioSpace
ACADIA Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Neuren updates on first quarter 2025 US sales of Daybue - Biotech Dispatch
Earnings call transcript: Acadia Pharmaceuticals beats Q1 2025 forecasts - Investing.com
Earnings call transcript: Acadia Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com UK
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
ACAD Q1 Revenue Surpasses Expectations, Reports Strong Patient Growth | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals Q1 2025 slides: revenue jumps 19%, pipeline timeline accelerated - Investing.com
Acadia Pharmaceuticals reports Q1 EPS 11c, consensus 11c - TipRanks
Earnings Flash (ACAD) Acadia Pharmaceuticals Reports Q1 Revenue $244.3M, vs. FactSet Est of $238.8M - marketscreener.com
ACADIA Pharmaceuticals Q1 2025 Earnings: EPS of $0.11 Beats Estimate, Revenue Surpasses Expectations at $244.3 Million - GuruFocus
Stock Watch: Can Acadia’s Rett Syndrome Drug Succeed? - insights.citeline.com
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference - BioSpace
Prader-Willi Syndrome Market to Reach New Heights in Growth - openPR.com
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference | ACAD Stock News - GuruFocus
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Acadia Pharmaceuticals CFO sells shares valued at $51,070 By Investing.com - Investing.com Canada
Acadia Pharmaceuticals CFO sells shares valued at $51,070 - Investing.com Australia
ACADIA Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Sees Price Target Cut by UBS | ACA - GuruFocus
UBS Adjusts ACADIA Pharmaceuticals Price Target to $22 From $25, Maintains Buy Rating - marketscreener.com
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 - BioSpace
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Acadia Pharmaceuticals (ACAD) Price Target Lowered by BofA Before Q1 Earnings | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals price target lowered to $18 from $19 at BofA - MSN
BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating - marketscreener.com
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):